These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29111092)

  • 1. Quantitative neuroimaging in mucopolysaccharidoses clinical trials.
    Nestrasil I; Vedolin L
    Mol Genet Metab; 2017 Dec; 122S():17-24. PubMed ID: 29111092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epilepsy in mucopolysaccharidosis disorders.
    Scarpa M; Lourenço CM; Amartino H
    Mol Genet Metab; 2017 Dec; 122S():55-61. PubMed ID: 29170080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses.
    Shapiro EG; Escolar ML; Delaney KA; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():8-16. PubMed ID: 29128371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical management of behavioral problems in mucopolysaccharidoses disorders.
    Escolar ML; Jones SA; Shapiro EG; Horovitz DDG; Lampe C; Amartino H
    Mol Genet Metab; 2017 Dec; 122S():35-40. PubMed ID: 29170079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical management of neurological manifestations of mucopolysaccharidosis disorders.
    Alden TD; Amartino H; Dalla Corte A; Lampe C; Harmatz PR; Vedolin L
    Mol Genet Metab; 2017 Dec; 122S():41-48. PubMed ID: 29153846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses.
    Rapoport DM; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():49-54. PubMed ID: 28964643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroimaging Findings in Patients with Mucopolysaccharidosis: What You Really Need to Know.
    Reichert R; Campos LG; Vairo F; de Souza CF; Pérez JA; Duarte JÁ; Leiria FA; Anés M; Vedolin LM
    Radiographics; 2016; 36(5):1448-62. PubMed ID: 27618324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
    Lau AA; Hemsley KM
    J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomical changes and pathophysiology of the brain in mucopolysaccharidosis disorders.
    Bigger BW; Begley DJ; Virgintino D; Pshezhetsky AV
    Mol Genet Metab; 2018 Dec; 125(4):322-331. PubMed ID: 30145178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique medical issues in adult patients with mucopolysaccharidoses.
    Mitchell J; Berger KI; Borgo A; Braunlin EA; Burton BK; Ghotme KA; Kircher SG; Molter D; Orchard PJ; Palmer J; Pastores GM; Rapoport DM; Wang RY; White K
    Eur J Intern Med; 2016 Oct; 34():2-10. PubMed ID: 27296591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucopolysaccharidoses: overview of neuroimaging manifestations.
    Nicolas-Jilwan M; AlSayed M
    Pediatr Radiol; 2018 Sep; 48(10):1503-1520. PubMed ID: 29752520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.
    Pan D
    Curr Pharm Biotechnol; 2011 Jun; 12(6):884-96. PubMed ID: 21235445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substrate reduction therapies for mucopolysaccharidoses.
    Jakóbkiewicz-Banecka J; Piotrowska E; Gabig-Cimińska M; Borysiewicz E; Słomińska-Wojewódzka M; Narajczyk M; Węgrzyn A; Węgrzyn G
    Curr Pharm Biotechnol; 2011 Nov; 12(11):1860-5. PubMed ID: 21902626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation.
    Seto T; Kono K; Morimoto K; Inoue Y; Shintaku H; Hattori H; Matsuoka O; Yamano T; Tanaka A
    Ann Neurol; 2001 Jul; 50(1):79-92. PubMed ID: 11456314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroimaging findings in patient series with mucopolysaccharidosis.
    Calleja Gero ML; González Gutiérrez-Solana L; López Marín L; López Pino MA; Fournier Del Castillo C; Duat Rodríguez A
    Neurologia; 2012 Sep; 27(7):407-13. PubMed ID: 22178048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic and neuroradiologic findings in the mucopolysaccharidoses.
    Lachman R; Martin KW; Castro S; Basto MA; Adams A; Teles EL
    J Pediatr Rehabil Med; 2010; 3(2):109-18. PubMed ID: 21791838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of CSF flow using phase-contrast MRI with ventriculomegaly and CSF opening pressure in mucopolysaccharidoses.
    Corte AD; de Souza CFM; Anés M; Maeda FK; Lokossou A; Vedolin LM; Longo MG; Ferreira MM; Perrone SGP; Balédent O; Giugliani R
    Fluids Barriers CNS; 2017 Sep; 14(1):23. PubMed ID: 28918752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.